Breast cancer genetics in African Americans

Authors

  • Olufunmilayo I. Olopade M.B., B.S.,

    Corresponding author
    1. Center for Clinical Cancer Genetics, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois
    • Center for Clinical Cancer Genetics, Department of Medicine, University of Chicago Medical Center, Chicago, IL 60637
    Search for more papers by this author
    • Fax: (773) 702-0963

  • James D. Fackenthal Ph.D.,

    1. Center for Clinical Cancer Genetics, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois
    Search for more papers by this author
  • Georgia Dunston Ph.D.,

    1. Howard University College of Medicine, Department of Microbiology, National Human Genome Center at Howard University, Washington, DC
    Search for more papers by this author
  • Michael A. Tainsky MD, Ph.D.,

    1. Karmanos Cancer Center, Detroit, Michigan
    Search for more papers by this author
  • Francis Collins M.D., Ph.D.,

    1. National Institutes of Health, National Human Genome Research Institute, Bethesda, Maryland
    Search for more papers by this author
  • Carolyn Whitfield-Broome Ph.D.

    1. Howard University College of Medicine, Department of Biochemistry and Molecular Biology, Howard University Cancer Center, National Human Genome Research Center at Howard University, Washington, DC
    Search for more papers by this author

Abstract

BACKGROUND

An overview of the state of genetic testing for BRCA1 and BRCA2 genes was presented at the Summit Meeting on Breast Cancer Among African American women.

METHODS

An exhaustive literature search was performed using PubMed and abstracts published from meetings of the American Association for Cancer Research, the American Society of Human Genetics, and the American Society of Clinical Oncology. The Breast Cancer Information Core was also searched for information regarding sequence variants in which the ethnicity of the individual tested was known.

RESULTS

Of the 26 distinct BRCA1 pathogenic mutations (protein-truncating, disease-associated missense, and splice variants) detected in Africans or African Americans, 15 (58%) have not been previously reported. In addition, 18 deleterious BRCA2 mutations have been identified and 10 (56%) of these are unique to the group. Only two pathogenic BRCA1 mutations (943ins10 and M1775R) have been detected in three or more unrelated families. However, seven additional BRCA1 or BRCA2 deleterious mutations have been reported in at least two unrelated families. Three of these recurrent BRCA1 mutations (943ins10, 1832del5, and 5296del4) have been characterized by haplotype studies and each likely arose from a common ancestor, including one ancestor that could be traced to the Ivory Coast in West Africa. Although only a few African-American families have been tested for BRCA1 and BRCA2 mutations, the probability of finding a mutation is invariably dependent on the age of onset and the number of breast and/or ovarian cancer cases in the family. The psychosocial implications of genetic testing for African Americans have not been well studied, so that high-risk African Americans may underestimate their risks of breast and ovarian cancer.

CONCLUSIONS

Deleterious BRCA1 and BRCA2 mutations have been identified in African-American and African families. A number of unique mutations have been described, but recurrent mutations are widely dispersed and are not readily identifiable in the few families that have been tested. Access to genetic counseling and testing in a culturally sensitive research setting must remain a high priority before genetic testing can be disseminated in the community. Cancer 2003;97(1 Suppl):236–45. © 2003 American Cancer Society.

DOI 10.1002/cncr.11019

Ancillary